S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
Log in
NYSE:NVRO

Nevro Stock Forecast, Price & News

$151.12
-4.58 (-2.94 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$146.66
Now: $151.12
$158.50
50-Day Range
$155.70
MA: $172.94
$182.18
52-Week Range
$65.05
Now: $151.12
$188.14
Volume588,045 shs
Average Volume443,259 shs
Market Capitalization$5.23 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.02
Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. It also offers Senza II system and Senza Omnia system products for chronic pain. The company's solution for chronic pain also includes HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. Nevro Corp. sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was founded in 2006 and is headquartered in Redwood City, California.
Nevro logo

Headlines

Nevro Corp. 2020 Q4 - Results - Earnings Call Presentation
February 26, 2021 |  seekingalpha.com
Recap: Nevro Q4 Earnings
February 25, 2021 |  benzinga.com
Recap: Nevro Q4 Earnings - Yahoo Finance
February 25, 2021 |  finance.yahoo.com
Nevro Q4 2020 Earnings Preview - Seeking Alpha
February 23, 2021 |  seekingalpha.com
Nevro Corp.'s (NYSE:NVRO) Path To Profitability
January 21, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone650-251-0005
Employees853
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$390.26 million
Book Value$6.98 per share

Profitability

Net Income$-103,690,000.00

Miscellaneous

Market Cap$5.23 billion
Next Earnings Date5/4/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.40 out of 5 stars

Medical Sector

606th out of 1,969 stocks

Surgical & Medical Instruments Industry

64th out of 169 stocks

Analyst Opinion: 3.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$151.12
-4.58 (-2.94 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NVRO News and Ratings via Email

Sign-up to receive the latest news and ratings for NVRO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Nevro (NYSE:NVRO) Frequently Asked Questions

Is Nevro a buy right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last twelve months. There are currently 3 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Nevro stock.
View analyst ratings for Nevro
or view top-rated stocks.

What stocks does MarketBeat like better than Nevro?

Wall Street analysts have given Nevro a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Nevro wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Nevro's next earnings date?

Nevro is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Nevro
.

How were Nevro's earnings last quarter?

Nevro Corp. (NYSE:NVRO) issued its quarterly earnings data on Tuesday, February, 23rd. The medical equipment provider reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.12. Nevro had a negative trailing twelve-month return on equity of 30.25% and a negative net margin of 24.46%.
View Nevro's earnings history
.

How has Nevro's stock been impacted by Coronavirus?

Nevro's stock was trading at $109.82 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NVRO stock has increased by 37.6% and is now trading at $151.12.
View which stocks have been most impacted by COVID-19
.

What guidance has Nevro issued on next quarter's earnings?

Nevro updated its FY 2021 After-Hours earnings guidance on Wednesday, February, 24th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $430-450 million, compared to the consensus revenue estimate of $451.19 million.

What price target have analysts set for NVRO?

14 equities research analysts have issued 1-year target prices for Nevro's stock. Their forecasts range from $100.00 to $217.00. On average, they expect Nevro's stock price to reach $181.38 in the next year. This suggests a possible upside of 20.0% from the stock's current price.
View analysts' price targets for Nevro
or view top-rated stocks among Wall Street analysts.

Who are Nevro's key executives?

Nevro's management team includes the following people:
  • Mr. D. Keith Grossman, Chairman, CEO & Pres (Age 61, Pay $1.6M)
  • Mr. Kashif Rashid, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 47, Pay $705.96k)
  • Mr. Michael Collier Carter, VP of Global Sales (Age 49, Pay $841.82k)
  • Mr. Andrew H. Galligan, Exec. Officer (Age 65, Pay $812.72k)
  • Ms. Niamh Louise Pellegrini, Chief Commercial Officer (Age 54, Pay $853.27k)
  • Mr. Roderick H. MacLeod, Chief Financial Officer
  • Mr. Patrick Schmitz, VP of Operations (Age 61)
  • Ms. Julie D. Dewey, VP of Investor Relations & Corp. Communications (Age 60)
  • Mr. Neeraj Teotia, VP of Marketing (Age 46)
  • Ms. Lori M. Ciano, Chief HR Officer (Age 58)

What is D. Keith Grossman's approval rating as Nevro's CEO?

9 employees have rated Nevro CEO D. Keith Grossman on Glassdoor.com. D. Keith Grossman has an approval rating of 68% among Nevro's employees.

Who are some of Nevro's key competitors?

What other stocks do shareholders of Nevro own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), The Walt Disney (DIS), General Electric (GE), Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Adobe (ADBE) and Intuitive Surgical (ISRG).

What is Nevro's stock symbol?

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

Who are Nevro's major shareholders?

Nevro's stock is owned by many different retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (11.70%), BlackRock Inc. (10.81%), Jackson Square Partners LLC (3.58%), Lord Abbett & CO. LLC (2.18%), Nuveen Asset Management LLC (1.35%) and Northern Trust Corp (1.30%). Company insiders that own Nevro stock include Andrew H Galligan, Doug Alleavitch, Elizabeth H Weatherman, Kevin C Oboyle, Michael F Demane, Niamh Louise Pellegrini and Shawn Mccormick.
View institutional ownership trends for Nevro
.

Which major investors are selling Nevro stock?

NVRO stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Renaissance Technologies LLC, Castleark Management LLC, Jennison Associates LLC, Victory Capital Management Inc., Lisanti Capital Growth LLC, State of Wisconsin Investment Board, and ClariVest Asset Management LLC. Company insiders that have sold Nevro company stock in the last year include Michael F Demane, Niamh Louise Pellegrini, and Shawn Mccormick.
View insider buying and selling activity for Nevro
or view top insider-selling stocks.

Which major investors are buying Nevro stock?

NVRO stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, BlackRock Inc., Jackson Square Partners LLC, Thornburg Investment Management Inc., Tiger Eye Capital LLC, Nuveen Asset Management LLC, Healthcare of Ontario Pension Plan Trust Fund, and Healthcare of Ontario Pension Plan Trust Fund. Company insiders that have bought Nevro stock in the last two years include Elizabeth H Weatherman, and Kevin C Oboyle.
View insider buying and selling activity for Nevro
or or view top insider-buying stocks.

How do I buy shares of Nevro?

Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nevro's stock price today?

One share of NVRO stock can currently be purchased for approximately $151.12.

How much money does Nevro make?

Nevro has a market capitalization of $5.23 billion and generates $390.26 million in revenue each year. The medical equipment provider earns $-103,690,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis.

How many employees does Nevro have?

Nevro employs 853 workers across the globe.

What is Nevro's official website?

The official website for Nevro is www.nevro.com.

Where are Nevro's headquarters?

Nevro is headquartered at 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065.

How can I contact Nevro?

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected]


This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.